{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T19:19:26Z","timestamp":1785007166329,"version":"3.55.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,1,20]],"date-time":"2025-01-20T00:00:00Z","timestamp":1737331200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,1,20]],"date-time":"2025-01-20T00:00:00Z","timestamp":1737331200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Hangzhou Joint Fund of the Zhejiang Provincial Natural Science Foundation of China","award":["LHZY24H310001"],"award-info":[{"award-number":["LHZY24H310001"]}]},{"DOI":"10.13039\/501100003786","name":"Science and Technology Bureau of Hangzhou","doi-asserted-by":"crossref","award":["20220919Y039"],"award-info":[{"award-number":["20220919Y039"]}],"id":[{"id":"10.13039\/501100003786","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100003786","name":"Science and Technology Bureau of Hangzhou","doi-asserted-by":"crossref","award":["20220919Y042"],"award-info":[{"award-number":["20220919Y042"]}],"id":[{"id":"10.13039\/501100003786","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["22107092"],"award-info":[{"award-number":["22107092"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Divers"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s11030-025-11111-y","type":"journal-article","created":{"date-parts":[[2025,1,20]],"date-time":"2025-01-20T02:55:18Z","timestamp":1737341718000},"page":"5709-5724","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Molecular modeling aided design, synthesis and biological evaluation of quinazoline derivatives for the treatment of human cancer"],"prefix":"10.1007","volume":"29","author":[{"given":"Cai-Shi","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin-Peng","family":"Tong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ze-Yu","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Meng","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting-Ting","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shou-Rong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,20]]},"reference":[{"key":"11111_CR1","doi-asserted-by":"publisher","first-page":"115917","DOI":"10.1016\/j.ejmech.2023.115917","volume":"262","author":"J Guo","year":"2023","unstructured":"Guo J (2023) Recent advances in the synthesis and activity of analogues of bistetrahydroisoquinoline alkaloids as antitumor agents. Eur J Med Chem 262:115917. https:\/\/doi.org\/10.1016\/j.ejmech.2023.115917","journal-title":"Eur J Med Chem"},{"key":"11111_CR2","doi-asserted-by":"publisher","first-page":"139905","DOI":"10.1016\/j.molstruc.2024.138805","volume":"1315","author":"KS Lee","year":"2024","unstructured":"Lee KS, Nada H, Gul AR, Elkamhawy A, Al-Karmalawy AA, Park TJ, Lee KY, Choi Y (2024) Targeting breast cancer with rationally designed quinazolines: a scaffold hopping strategy. J Mol Struct 1315:139905. https:\/\/doi.org\/10.1016\/j.molstruc.2024.138805","journal-title":"J Mol Struct"},{"key":"11111_CR3","doi-asserted-by":"publisher","first-page":"134915","DOI":"10.1016\/j.molstruc.2023.134915","volume":"1278","author":"M Naziri","year":"2023","unstructured":"Naziri M, Mokhtary M, Safa F (2023) New substituted quinazoline analogs: synthesis, anticancer evaluation and docking study. J Mol Struct 1278:134915. https:\/\/doi.org\/10.1016\/j.molstruc.2023.134915","journal-title":"J Mol Struct"},{"key":"11111_CR4","doi-asserted-by":"publisher","first-page":"3484","DOI":"10.1021\/acs.jmedchem.7b00322","volume":"60","author":"M Ahmad","year":"2017","unstructured":"Ahmad M, Aga MA, Bhat JA, Kumar B, Rouf A, Capalash N, Mintoo MJ, Kumar A, Mahajan P, Mondhe DM, Nargotraill A, Sharma PR, Zargar MA, Vishwakarma RA, Shah BA, Taneja SC, Hamid A (2017) Exploring derivatives of quinazoline alkaloid L-vasicine as cap groups in the design and biological mechanistic evaluation of novel antitumor histone deacetylase inhibitors. J Med Chem 60:3484\u20133497. https:\/\/doi.org\/10.1021\/acs.jmedchem.7b00322","journal-title":"J Med Chem"},{"key":"11111_CR5","doi-asserted-by":"publisher","first-page":"e202300681","DOI":"10.1002\/cbdv.202300681","volume":"20","author":"GS Bhat","year":"2023","unstructured":"Bhat GS, Mohammad FS (2023) Computational fragment-based design of phytochemical derivatives as EGFR inhibitors. Chem Biodivers 20:e202300681. https:\/\/doi.org\/10.1002\/cbdv.202300681","journal-title":"Chem Biodivers"},{"key":"11111_CR6","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1080\/07391102.2021.2003862","volume":"41","author":"RM Adamu","year":"2023","unstructured":"Adamu RM, Ibrahim B, Ibrahim MA, Balogun EO (2023) Identification of megacerotonic acid and a quinazoline derivative from Universal Natural Product Database as potential inhibitors of Trypanosoma brucei brucei alternative oxidase: molecular docking, molecular dynamic simulation and MM\/PBSA analysis. J Biomol Struct Dyn 41:45\u201354. https:\/\/doi.org\/10.1080\/07391102.2021.2003862","journal-title":"J Biomol Struct Dyn"},{"key":"11111_CR7","doi-asserted-by":"publisher","first-page":"245","DOI":"10.2478\/acph-2021-0020","volume":"71","author":"QF Zeno","year":"2021","unstructured":"Zeno QF, Luo CR, Cho JL, Lai DN, Shen XC, Zhang XY, Zhou W (2021) Tryptanthrin exerts anti-breast cancer effects both in vitro and in vivo through modulating the inflammatory tumor microenvironment. Acta Pharm 71:245\u2013266. https:\/\/doi.org\/10.2478\/acph-2021-0020","journal-title":"Acta Pharm"},{"key":"11111_CR8","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1016\/j.bmc.2018.12.032","volume":"27","author":"Y Li","year":"2019","unstructured":"Li Y, Xiao J, Zhang QZ, Yu WM, Liu MQ, Guo Y, He J, Liu YM (2019) The association between anti-tumor potency and structure-activity of protein-kinases inhibitors based on quinazoline molecular skeleton. Bioorgan Med Chem 27:568\u2013577. https:\/\/doi.org\/10.1016\/j.bmc.2018.12.032","journal-title":"Bioorgan Med Chem"},{"key":"11111_CR9","doi-asserted-by":"publisher","first-page":"3588","DOI":"10.1021\/acs.jmedchem.2c02115","volume":"66","author":"L Tan","year":"2023","unstructured":"Tan L, Wu CY, Zhang JF, Yu QW, Wang XY, Zhang LL, Ge MY, Wang ZJ, Ouyang L, Wang YX (2023) Design, synthesis, and biological evaluation of heterocyclic-fused pyrimidine chemotypes guided by X-ray crystal structure with potential antitumor and anti-multidrug resistance efficacy targeting the colchicine binding site. J Med Chem 66:3588\u20133620. https:\/\/doi.org\/10.1021\/acs.jmedchem.2c02115","journal-title":"J Med Chem"},{"key":"11111_CR10","doi-asserted-by":"publisher","first-page":"514","DOI":"10.2174\/0118715206276286231220055233","volume":"24","author":"A Dash","year":"2024","unstructured":"Dash A, Vaddamanu G, Karreddula R, Manubolu SSB, Kumari GP, Mulakayala N (2024) Novel N-(3-ethynyl Phenyl)-6,7-bis(2-methoxyethoxy)quinazoline-4-amine derivatives: synthesis, characterization, anti-cancer activity, in silico and DFT studies. Ant-Cancer Agent 24:514\u2013532. https:\/\/doi.org\/10.2174\/0118715206276286231220055233","journal-title":"Ant-Cancer Agent"},{"key":"11111_CR11","doi-asserted-by":"publisher","first-page":"14599","DOI":"10.1111\/cbdd.14599","volume":"104","author":"FS Tokali","year":"2024","unstructured":"Tokali FS, Senol H, Atesoglu S, Akbas F (2024) A series of quinazolin-4(3H)-one-morpholine hybrids as anti-lung-cancer agents: Synthesis, molecular docking, molecular dynamics, ADME prediction and biological activity studies. Chem Biol & Drug Des 104:14599. https:\/\/doi.org\/10.1111\/cbdd.14599","journal-title":"Chem Biol & Drug Des"},{"key":"11111_CR12","doi-asserted-by":"publisher","first-page":"e202300146","DOI":"10.1002\/cbdv.202300146","volume":"20","author":"J Sun","year":"2023","unstructured":"Sun J, Fang ZY, Tao YN, Zhang YH, Zhang Y, Sun HY, Zhou Y, Wu YF (2023) Design, synthesis and antitumor activity of FAK\/PLK1 dual inhibitors with quinazolinone as the skeleton. Chem Biodivers 20:e202300146. https:\/\/doi.org\/10.1002\/cbdv.202300146","journal-title":"Chem Biodivers"},{"key":"11111_CR13","doi-asserted-by":"publisher","first-page":"116246","DOI":"10.1016\/j.bcp.2024.116246","volume":"224","author":"M Yang","year":"2024","unstructured":"Yang M, Xiang H, Luo GS (2024) Targeting focal adhesion kinase (FAK) for cancer therapy: FAK inhibitors, FAK-based dual-target inhibitors and PROTAC degraders. Biochem Pharmacol 224:116246. https:\/\/doi.org\/10.1016\/j.bcp.2024.116246","journal-title":"Biochem Pharmacol"},{"key":"11111_CR14","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1038\/nrd3184","volume":"9","author":"K Strebhardt","year":"2010","unstructured":"Strebhardt K (2010) Multifaceted polo-like kinases: drug targets and antitargets for cancer therapy. Nat Rev Drug Discov 9:643-U24. https:\/\/doi.org\/10.1038\/nrd3184","journal-title":"Nat Rev Drug Discov"},{"key":"11111_CR15","doi-asserted-by":"publisher","first-page":"1274209","DOI":"10.3389\/fphar.2024.1274209","volume":"15","author":"HH Hu","year":"2024","unstructured":"Hu HH, Wang SQ, Shang HL, Lv HF, Chen BB, Gao SG, Chen XB (2024) Roles and inhibitors of FAK in cancer: current advances and future directions. Front Pharmacol 15:1274209. https:\/\/doi.org\/10.3389\/fphar.2024.1274209","journal-title":"Front Pharmacol"},{"key":"11111_CR16","doi-asserted-by":"publisher","DOI":"10.1186\/s40164-023-00446-7","author":"XM Tan","year":"2023","unstructured":"Tan XM, Yan YH, Song B, Zhu SL, Mei Q, Wu KM (2023) Focal adhesion kinase: from biological functions to therapeutic strategies. Exp Hematol Oncol. https:\/\/doi.org\/10.1186\/s40164-023-00446-7","journal-title":"Exp Hematol Oncol"},{"key":"11111_CR17","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.molstruc.2016.02.057","volume":"1115","author":"SS Parveen","year":"2016","unstructured":"Parveen SS, Al-Alshaikh MA, Panicker CY, El-Emam AA, Arisoy M, Temiz-Arpaci O, Van Alsenoy C (2016) Synthesis, vibrational spectroscopic investigations, molecular docking, antibacterial and antimicrobial studies of 5-ethylsulphonyl-2-(p-aminophenyl)benzoxazole. J Mol Struct 1115:94\u2013104. https:\/\/doi.org\/10.1016\/j.molstruc.2016.02.057","journal-title":"J Mol Struct"},{"key":"11111_CR18","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1080\/13543776.2024.2379924","volume":"34","author":"SR Bian","year":"2024","unstructured":"Bian SR, Zhang R, Nie JY, Zhu MX, Xie ZL, Liao CZ, Wang Q (2024) Progress with polo-like kinase (PLK) inhibitors: a patent review (2018-present). Expert Opin Ther Pat 34:789\u2013806. https:\/\/doi.org\/10.1080\/13543776.2024.2379924","journal-title":"Expert Opin Ther Pat"},{"key":"11111_CR19","doi-asserted-by":"publisher","first-page":"4099","DOI":"10.1002\/cbf.4099","volume":"42","author":"H Kulkarni","year":"2024","unstructured":"Kulkarni H, Dagar N, Gaikwad AB (2024) Targeting polo-like kinase 1 to treat kidney diseases. Cell Biochem Funct 42:4099. https:\/\/doi.org\/10.1002\/cbf.4099","journal-title":"Cell Biochem Funct"},{"key":"11111_CR20","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1080\/17460441.2023.2159942","volume":"18","author":"JM Stafford","year":"2023","unstructured":"Stafford JM, Wyatt MD, McInnes C (2023) Mclnnes Inhibitors of the PLK1 polo-box domain: drug design strategies and therapeutic opportunities in cancer. Expert Opin Drug Dis 18:65\u201381. https:\/\/doi.org\/10.1080\/17460441.2023.2159942","journal-title":"Expert Opin Drug Dis"},{"key":"11111_CR21","doi-asserted-by":"publisher","first-page":"101815","DOI":"10.1016\/j.jscs.2024.101815","volume":"28","author":"J Sun","year":"2024","unstructured":"Sun J, Zheng Q, Liu CS, Chen CH, Yan SP, Guo XM, Hu SP, Zhou Y, Wu YF (2024) Structure-Activity relationship (SAR) of 18\u03b2-glycyrrhetinic acid derivatives on their antitumor activity through the PPAR\u03b3 receptor and caspase-3 pathway. J Saudi Chem Soc 28:101815. https:\/\/doi.org\/10.1016\/j.jscs.2024.101815","journal-title":"J Saudi Chem Soc"},{"key":"11111_CR22","doi-asserted-by":"publisher","first-page":"136742","DOI":"10.1016\/j.molstruc.2023.136742","volume":"1295","author":"XM Guo","year":"2024","unstructured":"Guo XM, Xu MJ, Zheng Q, Li DD, Cheng L, Sun J, Wu ZM (2024) Biological evaluation of carbazoyl hydrazine derivatives as potential Pim-1kinase inhibitors for the treatment of human liver cancer. J Mol Struct 1295:136742. https:\/\/doi.org\/10.1016\/j.molstruc.2023.136742","journal-title":"J Mol Struct"},{"key":"11111_CR23","doi-asserted-by":"publisher","first-page":"42717","DOI":"10.1038\/srep42717","volume":"7","author":"A Daina","year":"2017","unstructured":"Daina A, Michielin O, Zoete V (2017) SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. Sci Rep 7:42717. https:\/\/doi.org\/10.1038\/srep42717","journal-title":"Sci Rep"}],"container-title":["Molecular Diversity"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11030-025-11111-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11030-025-11111-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11030-025-11111-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T12:28:55Z","timestamp":1763728135000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11030-025-11111-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,20]]},"references-count":23,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["11111"],"URL":"https:\/\/doi.org\/10.1007\/s11030-025-11111-y","relation":{},"ISSN":["1381-1991","1573-501X"],"issn-type":[{"value":"1381-1991","type":"print"},{"value":"1573-501X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,20]]},"assertion":[{"value":"28 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have affirmed that they do not have any financial or interpersonal conflicts that would have impacted to influence the presented and discussed work in this paper. The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}